OCUL - オキュラ―・セラピュ―ティクス (Ocular Therapeutix Inc.) オキュラ―・セラピュ―ティクス

 OCULのチャート


 OCULの企業情報

symbol OCUL
会社名 Ocular Therapeutix Inc (オキュラ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 オキュラー・セラピューティクス(Ocular Therapeutix Inc.)は独自のヒドロゲルプラットフォーム技術を使用して、目の病気と症状の治療法の開発・製造・商業化に従事するバイオ医薬品会社である。鉛管内使用のための主要製品候補であるDEXTENZA(デキサメタゾンインサート)は眼科手術後の眼の痛みおよび炎症の治療のための第III相臨床開発を完了した。OTX-TP(トラボプロストインサート)は、緑内障および高眼圧症の第III相臨床開発にある。その初期段階の資産には、中等度から重度の緑内障および高眼圧症の治療のための持続放出性トラボプロスト眼内注射、並びに網膜疾患の治療のための徐放性硝子体内注射であるOTX-TICが含まれる。これらの注射には、チロシンキナーゼ阻害剤であるOTX-TKIの開発、および延長された放出タンパク質ベースの抗血管内皮成長因子トラップであるRegeneronとの共同研究が含まれる。   オキュラ―・セラピュ―ティクスは眼疾患の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。ポリエチレン・グリコ―ルを基盤にしたヒドロゲルの点眼剤を開発。白内障切開部の閉鎖剤「リシュア」を販売するほか、白内障術後の眼炎症・疼痛のOTX-DP、緑内障と高眼圧症の治療薬OTX-TPの治験を行う。   
本社所在地 15 Crosby Drive Bedford MA 01730 USA
代表者氏名 Amarpreet Sawhney Amarpreet Sawhney
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 781-895-3235
設立年月日 38961
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.ocutx.com
nasdaq_url https://www.nasdaq.com/symbol/ocul
adr_tso
EBITDA EBITDA(百万ドル) -52.79000
終値(lastsale) 6.14
時価総額(marketcap) 236955997.48
時価総額 時価総額(百万ドル) 238.11380
売上高 売上高(百万ドル) 1.99800
企業価値(EV) 企業価値(EV)(百万ドル) 196.90980
当期純利益 当期純利益(百万ドル) -56.23800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ocular Therapeutix Inc revenues increased 8% to $988K. Net loss decreased 21% to $27.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Selling and Marketing - Balancing value decrease of 89% to $1.4M (expense) Stock-based Compensation in SGA decrease of 52% to $226K (expense).

 OCULのテクニカル分析


 OCULのニュース

   Raymond James Stick to Their Buy Rating for Ocular Therapeutix By Investing.com  2021/03/12 12:17:14 Investing.com
Raymond James Stick to Their Buy Rating for Ocular Therapeutix
   Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update  2021/03/11 21:01:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided updates on its leading ophthalmology pipeline. “The fourth quarter marked considerable commercial, clinical and regulatory progress for the Company,” said Antony Mattess
   Head to Head Survey: Ocular Therapeutix (NASDAQ:OCUL) vs. Amicus Therapeutics (NASDAQ:FOLD)  2021/03/10 08:04:41 Modern Readers
Ocular Therapeutix (NASDAQ:OCUL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Ocular Therapeutix and Amicus […]
   Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis  2021/03/04 21:01:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has set an action date under the Prescriptio
   Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease - Stocks News Feed  2021/03/01 18:03:15 Stocks News Feed
Ocular Therapeutix Inc (NASDAQ: OCUL) has dosed the first patient in its Phase 2 trial evaluating OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the signs and symptoms of dry eye disease. OTX-DED is a physician-administered, preservative-free intracanalicular insert designed to deliver either 0.2 or 0.3 mg doses of dexamethasone. The 150-subject study is designed to assess… Read More »Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease
   Raymond James Stick to Their Buy Rating for Ocular Therapeutix By Investing.com  2021/03/12 12:17:14 Investing.com
Raymond James Stick to Their Buy Rating for Ocular Therapeutix
   Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update  2021/03/11 21:01:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided updates on its leading ophthalmology pipeline. “The fourth quarter marked considerable commercial, clinical and regulatory progress for the Company,” said Antony Mattess
   Head to Head Survey: Ocular Therapeutix (NASDAQ:OCUL) vs. Amicus Therapeutics (NASDAQ:FOLD)  2021/03/10 08:04:41 Modern Readers
Ocular Therapeutix (NASDAQ:OCUL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Ocular Therapeutix and Amicus […]
   Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis  2021/03/04 21:01:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has set an action date under the Prescriptio
   Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease - Stocks News Feed  2021/03/01 18:03:15 Stocks News Feed
Ocular Therapeutix Inc (NASDAQ: OCUL) has dosed the first patient in its Phase 2 trial evaluating OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the signs and symptoms of dry eye disease. OTX-DED is a physician-administered, preservative-free intracanalicular insert designed to deliver either 0.2 or 0.3 mg doses of dexamethasone. The 150-subject study is designed to assess… Read More »Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease
   Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences  2021/02/24 13:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Cowen 41st Annual Health Care Conference Date: Monday, March 1, 2021 Analyst-hosted fireside chat: 12:30 PM ET Raymond James 42nd Annual Institutional Investors Conference Date: Wednesday, March 3, 20
   Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition  2021/02/12 13:00:00 Business Wire
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
   Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  2021/02/04 21:01:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted (i) a non-statutory stock option to purchase up to an aggregate of 100,000 shares of common stock of Ocular Therapeutix subject to time-based vesting (the “Time-Based Option”) and (ii) a non-statutory stock option to purchase up to an
   Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum  2021/01/20 13:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension at the Glaucoma 360 New Horizons Forum being held virtually on January 30th. As part of the event,
   Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development  2021/01/07 13:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 オキュラ―・セラピュ―ティクス OCUL Ocular Therapeutix Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)